Phase II study of peptide vaccination for patients with metastatic lung or gastro-intestinal tract cancers
Phase 1
- Conditions
- lung cancer, pharyngeal cancer, gastric cancer, jejunal cancer, ileal cancer, pancreas cancer, biliary tract cancer, soft tissue sarcoma
- Registration Number
- JPRN-UMIN000002857
- Lead Sponsor
- Tohoku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
1) HIV positive patients 2) severe comorbidity (respiratory disease, immunological disease, coagulation disorders, etc) 3) pregnant woman
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of efficacy by RECIST criteria
- Secondary Outcome Measures
Name Time Method Overall survival, Responsive rate, TTF, Immunological responses by peptide vaccination (CTL, CD8, regT)